Difficulties in the Treatment of Essential Thrombocythemia

Authors

  • R.G. Mihaila “Lucian Blaga” University of Sibiu, Romania
  • S. Marchian “Lucian Blaga” University of Sibiu, Romania
  • M. Cernusca-Mitariu “Lucian Blaga” University of Sibiu, Romania
  • R.C. Cipaian “Lucian Blaga” University of Sibiu, Romania

Keywords:

anagrelide, essential thrombocythemia, hydroyurea

Abstract

In essential thrombocythemia there is an inflammatory status, which predisposes to genomic instability and atherosclerosis development. The treatment of essential thrombocythemia may have adverse effects some of them may influence the development of associated diseases. A patient diagnosed with essential thrombocythemia 9 years ago showed liver cytolysis during the therapy with hydroxyurea. An increase in blood pressure was showed after stopping it and introducing anagrelide. The solution was combined treatment with lower doses of each product for the diminishing of side effects.

Downloads

Published

2014-01-07

Issue

Vol. 6(55) No. 2 (2013)

Section

MEDICAL SCIENCES